KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue154250229
Cost of Revenue---
Gross Profit154250229
Operating Expenses
Research Development86,93897,74460,127
Selling General and Administrative23,94821,58215,948
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-110,732-119,076-75,846
Income from Continuing Operations
Total Other Income/Expenses Net1,29489570
Earnings Before Interest and Taxes-109,438-118,181-75,776
Interest Expense--1
Income Before Tax-109,438-118,181-75,777
Income Tax Expense139--
Minority Interest---
Net Income From Continuing Ops-109,577-118,181-75,777
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-109,577-118,181-75,777
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-109,577-118,181-75,777